An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2015
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 22 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 06 Mar 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 17 Dec 2013 New trial record